Vascular Gene Therapy in the 21st Century

• References

• 1 Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 01: 964-966
• 2 Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932
• 3 Nabel EG, Nabel GJ. Gene transfer. In: Fuster V, Ross R, Topol EJ. eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven. 1996: 739-756
• 4 Finkel T, Epstein SE. Gene therapy for vascular disease. FASEB J 1995; 09: 843-851
• 5 Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989; 80: 1347-1353
• 6 Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science 1989; 244: 1344-1346
• 7 Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989; 244: 1342-1344
• 8 Miller AD, Trauber DR, Buttimore C. Factors involved in production of helper virus-free retrovirus vectors. Somatic Cell Mol Genet 1986; 12: 175-183
• 9 Gordon EM, Anderson WF. Gene therapy using retroviral vectors. Curr Opin Biotechnol 1994; 05: 611-616
• 10 Rivière I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737
• 11 Weiss AA, Tailor CS. Retrovirus receptors. Cell 1995; 82: 531-533
• 12 Russ AP, Friedel C, Grez M, Von Melchner H. Self-deleting retrovirus vectors for gene therapy. J Virol 1996; 70: 4927-4932
• 13 Clowes MM, Lynch CM, Miller AD, Miller DG, Osborne WRA, Clowes AW. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 1994; 93: 644-651
• 14 Casscells W, Willerson JT. Amphotropic but not atherotropic: Another caveat for adenoviral gene therapy. J Clin Invest 1995; 95: 2425-2426
• 15 Berns KI, Giraud C. Adenovirus and adeno-associated virus as vectors for gene therapy. Ann.NY Acad.Sci 1995; 772: 95-104
• 16 Marconi P, Krisky D, Oligino T. et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996; 93: 11319-11320
• 17 Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 1994; 05: 793-801
• 18 Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: Focus on cytomegalovirus. Lancet 1996; 348: S13-S17
• 19 Hendrix MGR, Salimans MMM, Van Boven CPA, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990; 136: 23-28
• 20 Ledley FD. Nonviral gene therapy: The promise of genes as pharmaceutical products. Hum Gene Ther 1995; 06: 1129-1144
• 21 Feigner PL, Tsai YJ, Sukhu L. et al. Improved cationic lipid formulations for in vivo gene therapy. Ann.NY Acad.Sci 1995; 772: 126-139
• 22 Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral Hposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93: 11421-11425
• 23 Grossman M, Raper SE, Kozarsky K. et al. Successful ex vivo gene therapy directed to liver in a patient with familial hyperc-holesterolaemia. Nature Genet 1994; 06: 335-341
• 24 Raper SE, Grossman M, Rader DJ. et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 1996; 223: 116-126
• 25 Kay MA, Landen CN, Rothenberg SR. et al. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357
• 26 Messina LM, Podrazik RM, Whitehill TA. et al. Adhesion and incorporation of lacZ-transduced endothelial cells into the intact capillary wall in the rat. Proc Natl Acad Sci USA 1992; 89: 12018-12022
• 27 Osborne WRA, Ramesh N, Lau S, Clowes MM, Dale DC, Clowes AW. Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 1995; 92: 8055-8058
• 28 Setoguchi Y, Danel C, Crystal RG. Stimulation of erythropoi-esis by in vivo gene therapy: Physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Blood 1994; 84: 2946-2953
• 29 Hamamori Y, Samal B, Tian J, Kedes L. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 1995; 95: 1808-1813
• 30 Tripathy SK, Svensson EC, Black HB. et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996; 93: 10876-10880
• 31 Örtenwall P, Wadenvik H, Risberg B. Reduced platelet deposition on seeded versus unseeded segments of expanded polytetrafluoroethylene grafts: Clinical observations after a 6-month follow-up. J Vase Surg 1989; 10: 374-380
• 32 Magometschnigg H, Kadletz M, Vodrazka M. et al. Prospective clinical study with in vitro endothelial cell lining of expanded polytetrafluoroethylene grafts in crural repeat reconstruction. J Vase Surg 1992; 15: 527-535
• 33 Zilla P, Deutsch M, Meinhart J. et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: An actuarial follow-up over three years. J Vase Surg 1994; 19: 540-548
• 34 Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996; 93: 301-309
• 35 Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nature Med 1996; 02: 293-298
• 36 Dzau VJ, Morishita R, Gibbons GH. Gene therapy for cardiovascular disease. Trends Biotechnol 1993; 11: 205-210
• 37 Von der Leyen HE, Gibbons GH, Morishita R. et al. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-1141
• 38 Morishita R, Gibbons GH, Horiuchi M. et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859
• 39 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
• 40 Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: Fact, fancy, and future. Circulation 1994; 90: 2070-2084
• 41 Fischell TA, Kharma BK, Fischell DR. et al. Low-dose, b-par-ticle emission from ‘stent’ wire results in complete, localized inhibition of smooth muscle cell proliferation. Circulation 1994; 90: 2956-2963
• 42 Waksman R, Robinson KA, Crocker IR. et al. Intracoronary low-dose b-irradiation inhibits neointima formation after coronary artery balloon injury in the swine restenosis model. Circulation 1995; 92: 3025-3031
• 43 Clowes AW. Intimal hyperplasia and graft failure. Cardiovasc Pathol 1993; 02: 179S-186S
• 44 Schwartz SM, DeBlois D, O’Brien ERM. The intima-Soil for atherosclerosis and restenosis. Circ Res 1995; 77: 445-465
• 45 Geary RL, Williams JK, Golden D, Brown DG, Benjamin ME, Adams MR. Time course of cellular proliferation, intimal hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis – A nonhuman primate model of restenosis. Arterioscler Thromb Vase Biol 1996; 16: 34-43
• 46 Scott NA, Cipolla GD, Ross CE. et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996; 93: 2178-2187
• 47 Mattsson E, Clowes AW. Current concepts in restenosis following balloon angioplasty. Trends Cardiovasc Med 1995; 05: 200-204
• 48 Nabel EG, Yang Z, Plautz G. et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogen-esis in arteries in vivo. Nature 1993; 362: 844-846
• 49 Nabel EG, Yang Z, Liptay S. et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 1993; 91: 1822-1829
• 50 Nabel EG, Shum L, Pompili VJ. et al. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocel-lular hyperplasia. Proc Natl Acad Sci USA 1993; 90: 10759-10763
• 51 Forough R, Koyama N, Hasenstab D. et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circulation Research 1996; 79: 812-820
• 52 Morishita R, Gibbons GH, Ellison KE. et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478
• 53 Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B_t and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 1994; 149: 13-19
• 54 Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisensec-myboligonucleotidesinhibitintimalarterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70
• 55 Epstein SE, Speir E, Finkel T. Do antisense approaches to the problem of restenosis make sense. Circulation 1993; 88: 1351-1353
• 56 Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by C-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-828
• 57 Edelman ER, Simons M, Sirois MG, Rosenberg RD. c-myc in vasculoproliferative disease. Circ Res 1995; 76: 176-182
• 58 Villa AE, Guzman LA, Poptic EJ. et al. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995; 76: 505-513
• 59 Burgess TL, Fisher EF, Ross SL. et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995; 92: 4051-4055
• 60 Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis – Some critical considerations. Circulation 1995; 92: 1981-1993
• 61 Chang MW, Barr E, Seltzer J. et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-522
• 62 Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995; 96: 2260-2268
• 63 Ohno T, Gordon D, San H. et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-484
• 64 Simari RD, San H, Rekhter M. et al. Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 1996; 98: 225-235
• 65 Knechtle SJ, Zhai Y, Fechner J. Gene therapy in transplantation. Transplant Immunology 1997; 04: 257-264
• 66 Dunn PF, Newman KD, Jones M. et al. Seeding of vascular grafts with genetically modified endothelial cells – Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation 1996; 93: 1439-1446
• 67 Clowes AW. Improving the interface between biomaterials and the blood – The gene therapy approach. Circulation 1996; 93: 1319-1320
• 68 Takeshita S, Rossow ST, Kearney M. et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995; 147: 1649-1660
• 69 Isner JM, Pieczek A, Schainfeld R. et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF₁₆₅ in patient with ischaemic limb. Lancet 1996; 348: 370-374
• 70 Allaire E, Forough R, Wang T, Clowes MM, Clowes AW. Tissue metalloproteinase inhibitor-1 (TIMP-1) overexpression prevents arterial rupture and dilation in a xenograft model. FASEB J 1997; 10: 782 [Abstract].